THERAPEUTIC EMBOLISATION side effect
What is THERAPEUTIC EMBOLISATION ?THERAPEUTIC EMBOLISATION : Entecavir Side Effects Report #5546315-5
Consumer or non-health professional from BRAZIL reported ENTECAVIR problem on Dec 05, 2007. Male patient, 63 years of age, was diagnosed with hepatitis b and was treated with ENTECAVIR. After drug was administered, patient experienced the following problems/side effects: hepatic neoplasm malignant, liver transplant, therapeutic embolisation, . ENTECAVIR dosage: unknown. During the same period patient was treated with LAMIVUDINE, GLIBENCLAMIDE. Patient was hospitalized. Patient recovered.
THERAPEUTIC EMBOLISATION : Gleevec Side Effects Report #5411753-8
GLEEVEC problem was reported by a Physician from JAPAN on Aug 08, 2007. Male patient, 77 years of age, weighting 183.0 lb, was diagnosed with gastrointestinal stromal tumour and was treated with GLEEVEC. After drug was administered, patient experienced the following problems/side effects: neoplasm malignant, therapeutic embolisation, . GLEEVEC dosage: 400 MG/D. Patient was hospitalized. Patient recovered.
THERAPEUTIC EMBOLISATION : Gleevec Side Effects Report #5401165-5
Physician from JAPAN reported GLEEVEC problem on July 27, 2007. Male patient, 77 years of age, weighting 183.0 lb, was diagnosed with gastrointestinal stromal tumour and was treated with GLEEVEC. After drug was administered, patient experienced the following problems/side effects: neoplasm malignant, therapeutic embolisation, . GLEEVEC dosage: 400 MG/D. Patient was hospitalized. Patient recovered.
THERAPEUTIC EMBOLISATION : Gleevec Side Effects Report #5401165-5
GLEEVEC problem was reported by a Physician from JAPAN on July 27, 2007. Male patient, 77 years of age, weighting 183.0 lb, was diagnosed with gastrointestinal stromal tumour and was treated with GLEEVEC. After drug was administered, patient experienced the following problems/side effects: neoplasm malignant, therapeutic embolisation, . GLEEVEC dosage: 400 MG/D. Patient was hospitalized. Patient recovered.